AstraZeneca’s oral GLP-1 advances to Phase III after strong trial results
Investing.com–AstraZeneca PLC (LON:) is advancing its oral GLP-1 receptor agonist elecoglipron into a Phase III clinical program after two mid-stage trials demonstrated meaningful weight loss and blood sugar reduction. Shares in the company rose 0.7% in after-hours trade. According to data from the VISTA Phase IIb trial, adults with obesity or who were overweight receiving…
